A cryophemer composition for use in the treatment of HIV-associated diarrhea or diarrhea associated with highly active antiretroviral therapy (HAART) in an HIV-positive subject by administration of about 250 mg to about 1000 mg per day； administration of approximately 250 mg per day； administration of approximately 500 mg per day； administration of approximately 1000 mg per day； administration of approximately 125 mg twice daily； administration of approximately 250 mg twice a day； or the administration of approximately 500 mg twice a day of cryptoelectric to the subject in need, optionally in which a subject is considered treated if the subject demonstrates one or more of a decrease in the number of bowel movements per day, a decrease in the number of aqueous bowel movements per day, an improvement in the daily abdominal score for pain or discomfort, an improvement in the daily stool consistency score, a decrease in stool consistency, a decrease in the number of days per week that the subject experiences urgency, a decrease in the number of days per week that the subject experiences faecal incontinence or a decrease in unscheduled visits due to a significant worsening of diarrhea.Una composición de crofelémero para su uso en el tratamiento de la diarrea asociada al VIH o la diarrea asociada a la terapia antirretrovírica altamente activa (TARGA) en un sujeto VIH positivo mediante la administración de aproximadamente 250 mg a aproximadamente 1000 mg por día； la administración de aproximadamente 250 mg por día； la administración de aproximadamente 500 mg por día； la administración de aproximadamente 1000 mg por día； la administración de aproximadamente 125 mg dos veces por día； la administración de aproximadamente 250 mg dos veces por día； o la administración de aproximadamente 500 mg dos veces por día de crofelémero al sujeto que lo necesite, opcionalmente en la que un sujeto se considera tratado si el sujeto demuestra uno o más de entre una disminución en el número d
